

AASLD Nov. 15-19, 2024
The Liver Meeting[®]



Program of Abstract Plenary and Abstract Parallel Sessions

ABSTRACT PLENARY SESSIONS

11/17/2024

8:30 am - 9:30 am

Liver Transplant Plenary

0003 - Optimal mean arterial pressure targets in the management of critically ill patients with decompensated cirrhosis and septic shock - Kavish Patidar, DO

0011 - Pre-emptive Administration of Continuous Renal Replacement Therapy in Patients with Acute Liver Failure with Cerebral Edema improves outcomes- A randomized controlled trial - Rakhi Maiwall, MD, DM

0012 - Applying Large Language Models to Better Understand Psychosocial Factors Contributing to Liver Transplant Waiting List Decisions - Emily Robitschek

0014 - Impact of Pre-Transplant Immune Checkpoint Inhibitors on Downstaging Outcomes: A Prospective Intention-to-Treat Analysis from a Multi-Center US Study - Parissa Tabrizian, MD, FACS

11/18/2024

11:30 am - 12:30 pm

Clinical Plenary #1

0001 - Clinically Distinct Metatypes of Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: An Unsupervised Machine Learning Analysis of Children Enrolled in NASH CRN Studies - Helaina E. Huneault, RD, PhD

0009 - Impact of Glucagon-like Peptide-1 Receptor Agonists on the Risk of Adverse Liver Outcomes among Patients with Alcohol-associated Liver Disease and Type 2 Diabetes. - Zayed Rashid, MD

0004 - Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles - Naga P. Chalasani

0013 - Fecal Microbiota Therapy is a safe and effective option in Steroid Ineligible Alcoholic Hepatitis (FEMTAH Trial): a RCT - Shiv Kumar Sarin, MD, DM, FAASLD

11/18/2024
8:30 am - 9:30 am

Clinical Plenary #2

0008 - Novel genetic architecture and metabolic interactions for all-cause cirrhosis and hepatocellular carcinoma defined in multi-ancestry meta-analyses - Marijana Vujkovic, PhD

0005 - Preemptive TIPS: the new standard for gastric variceal bleeding in patients with cirrhosis? Results of a large multicenter randomized controlled trial - Jean-Paul CERVONI, MD

0007 - Point-of-care Ultrasound (POCUS) to assess impact of Cirrhotic Cardiomyopathy and Renal Biomarkers in patients with cirrhosis and acute kidney injury - Madhumita Premkumar, MBBS, MD, DM

11/18/2024
11:30 am - 12:30 pm

Basic Science Plenary

0006 - Hepatic Artery Flow-Induced Portal Tract Remodeling and Fibrosis in Portal Hypertension: The Role of VCAM-1 and Osteopontin-Expressing Macrophages - Ruixue Ma

0002 - Identification of Novel Class I HLA Alleles and T-cell Repertoire Features Associated with Indeterminate Pediatric Acute Liver Failure - Catherine A. Chapin, MD

0015 - Targeting Macrophage-Mediated Mechanisms of Immune Evasion as adjuvant therapy in TACE-resistant Hepatocellular Carcinoma - Lea Lemaitre, PhD

0010 - Alcohol-induced trained immunity contributes to dysfunctional immune responses involving PD1 and exacerbated inflammation in mice and human immune cells - Prashanth Thevkar Nagesh, PhD

ABSTRACT PARALLEL SESSIONS

11/17/2024

8:00 am - 9:30 am

Hepatitis B- New Insights with Use of Approved Therapies

0108 - **Association Between Retreatment and Hepatitis B Surface Antigen Seroclearance in Patients with Clinical Relapses Following Withdrawal of Nucleos(t)ide Analogues** - *Yao-Chun Hsu, MD, MS, PhD, FAASLD*

0062 - **The efficacy of antiviral therapy for HBV-infected children: A large-scale, multicenter prospective study (Sprout Project) - an interim analysis** - *Hongfei Zhang*

0019 - **Association between viral replication activity and recurrence of HBV-associated hepatocellular carcinoma after curative resection** - *Won-Mook Choi, MD, PhD*

0125 - **Peginterferon alpha-2b combined with TDF promotes durable HBsAg loss in patients with chronic hepatitis B: a multicenter, randomized controlled, phase 3 clinical trial** - *Guiqiang Wang*

0204 - **A randomized controlled trial of tenofovir alafenamide prophylaxis in HBsAg-positive rheumatic patients treated with biologics** - *Yi-Hsiang Huang, MD, PhD*

0208 - **Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-based Treatment in Hepatitis B e Antigen-negative and Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B** - *Jeong JH. Heo, M.D., Ph.D.*

Portal Hypertension and Other Complications of Cirrhosis- New Scientific Discoveries

0223 - **Targeting Liver Lymphatic Drainage: A Novel Approach to Treat Liver Cirrhosis and Portal Hypertension** - *JAIN JEONG, PhD*

0224 - **Liver sinusoidal endothelial cell responses to hepatic congestion instigate β -catenin dependent proliferative responses in peri-central hepatocytes** - *Papawee Sutthirat, MS*

0165 - **Endurance exercise promotes favorable gut microbiome composition during hyperammonemia** - *Annette Bellar*

0246 - **Low shear induced hepatic kallikrein-kinin system activation regulates intrahepatic vascular adhesion and develops pro-thrombotic microenvironment** - *Dinesh Mani Tripathi, Ph.D*

0211 - **Carriage of the Z allele of the *SERPINA1* gene as a predisposing factor for the development of hepatorenal syndrome in patients with decompensated liver cirrhosis** - *Sona Frankova, MD*

0045 - **Injured hepatocytes-secreted extracellular vesicles promote cirrhosis-associated skeletal muscle injury through mtDNA-cGAS-STING axis** - *Yunke Peng*

MASLD and MASH- Natural History and Existing Therapy

0089 - **Long-term Liver-related Outcomes and Liver Fibrosis Progression of Statin Usage in Steatotic Liver Disease.** - *Xiao-Dong Zhou, MD*

0225 - **Liver Stiffness Measurement and Hepatocellular Carcinoma Risk in Metabolic Dysfunction Associated Steatotic Liver Disease** - *Binu John, MD, MPH, FAASLD*

0112 - **Effect of resmetirom or placebo in NASH fibrosis patients with <5% or ≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52 week serial liver biopsy study** - *Mazen Nouredin, MD, MHSc*

0147 - **Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is Significantly Associated with Biological Age and its Acceleration as Assessed by Methylation Clock** - *Naga P. Chalasani*

0203 - **Use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality** - *Alfred S. Barritt, IV, MD, MSCR, FAASLD*

0028 - **Aerobic exercise training leads to MASH resolution as defined by the MASH Resolution Index without body weight loss** - *Jonathan G. Stine, MD, MSc*

11/17/2024

11:00 am - 12:30 pm

Acute Liver Failure: Pathophysiology, Prognostication, and Management

0226 - **Selective ablation of FXR in neurons is neuroprotective in a mouse model of acute liver failure** - *Kathryn Rhodes, BA/BS*

0110 - **Acylcarnitines are promising indicators of infection and mortality associated in in patients with acute liver failure.** - *Anna Cavazza*

0131 - **Cryopreserved human alternatively activated macrophages promote the resolution of acetaminophen-induced liver injury** - *Maria Elena MC. Candela, PhD*

0064 - **Safety and efficacy of nafamostat mesylate anticoagulation in centrifugal artificial liver support system for ALF and ACLF patients at high risk of bleeding** - *Zhu Xinfang*

0103 - **DDX3X Regulates the Functional Transition of Endoplasmic Reticulum Stress During Progression of Liver Failure** - *Ling Xu, PhD*

0229 - **Plasma lipidomic and fungal peptide-based community analysis identifies distinct signatures of early mortality in acute liver failure** - *Shiv Kumar Sarin, MD, DM, FAASLD*

Liver Transplantation and Liver Surgery- Current State of Disparities in Liver Transplant

0025 - **Geographic Disparities in Liver Transplant Waitlist Outcomes for Critically Ill Candidates: The Impact of Population Density amid the Acuity Circle in the United States** - *Tomohiro Tanaka, MD, FAASLD*

0174 - **Current Burden and Geographic Disparities in Liver Mortality and Access to Liver Transplantation** - *Nicolas Rinella, BA*

0176 - **THE OPERATIONAL CHARACTERISTICS OF LIVER TRANSPLANT PROGRAMS DETERMINE GROWTH, AND IMPACT WHERE STATE LEVEL DISPARITIES IN TRANSPLANT ACCESS EXIST** - *Richard Gilroy*

0207 - **Racial Disparities in Access and Outcomes of Liver Transplant in the United States: An Update** - *Daniel Alejandro Gonzalez Mosquera, MD*

2556 - Racial and Gender Disparities in Access to Living Donor Liver Transplantation Between 1999-2021 - *Nicole Ng, MD*

0221 - Health system and patient predictors of post-transplant short-term mortality and length of stay among liver transplant recipients - *Joyce Tien*

Hepatobiliary Neoplasia- Early Detection and Prediction of Response

0188 - Towards precision oncological liver surgery: label-free multiphoton microscopy and machine learning for tumor recognition in hepatocellular carcinoma - *Carina E. Riediger, Prof., MD, MSc*

0024 - Integrative Multiomics Unveils the Aggressive Mechanisms and Therapeutic Strategies of CA19-9 Positive Intrahepatic Cholangiocarcinoma - *Delin Ma, MD*

0132 - DNA methylation of tumor tissues and circulating tumor DNA in early detection of hepatocellular carcinoma - *Siyu Fu*

0197 - "Molecular Classification of Hepatocellular Carcinoma on Non-Cirrhotic Background: Integrating Immunohistochemistry Panel and Genomic Analysis" - *Khushboo Agrawal*

0083 - Novel multiomics Biomarker Signature derived from blood circulating Hepatocyte-Extracellular Vesicles for the early detection of HCC - *Tomas Dias, BA/BS, MS, PhD*

3401 - The optimal AFP threshold for HCC screening should be lower than 20 ng/mL in cured hepatitis C, ALD, and MASLD - *Nicole J. Kim, MD, MPH*

Advances in Pediatric Liver Disease: Clinical

0161 - Clinical Status and Liver Histology at Liver Transplantation in Progressive Familial Intrahepatic Cholestasis – Experiences from the Childhood Liver Disease Research Network. - *Paula Hertel, MD*

0172 - Clinical Factors Impacting the Health-Related Quality of Life of Children and Young Adults with Autoimmune Liver Disease - *Rebecca Farr, MD*

0232 - An Ultrasound Approach to Visualize the “Duct at the Hilum” in Infants Undergoing Evaluation for Biliary Atresia - *Ashley Upton, BS, RDMS, RVT*

0076 - Serum IgG reflects histological activity in children with autoimmune hepatitis - Or Steg Saban, MD

0056 - Decline of Pediatric Acute Hepatitis of Unknown Etiology During the Coronavirus Disease 2019 Pandemic in Japan. - Hiroki Kondou, MD, PhD

0184 - Improvements in pruritus are associated with improvements in growth in patients with progressive familial intrahepatic cholestasis: Data from the MARCH-ON trial - Alexander Miethke, MD

11/17/2024

2:00 pm - 3:30 pm

Translational Strategies for Inflammatory-Driven Liver Disease: Immune Modulation and Tissue Remodeling

0031 - Immune checkpoint B7-H4 promotes cholangiocarcinoma growth via TGF β -induced stromal remodeling, unveiling a novel *targetable* tumor-stroma axis - Emily Bramel, BS

0017 - The distinct expression patterns of ENO1 in malignant cells and CD8+ T cells play a crucial role in shaping the "evolution tree" of HCC - Jing He

0241 - HEPATOCYTE-SPECIFIC DELETIONS OF AUTOPHAGY-INITIATING GENES RESULT IN PRONOUNCED HEPATOMEGALY AND PATHOLOGY - Ta-Chiang Liu, MD, Ph.D.

0060 - Kupffer cell repopulation after toxic depletion results from propagation of embryonic KCs and not from maturation of monocyte-derived replacements - Kyle Yuquimpo, DO

0047 - Dietary Salt Intake Modulates Th17-Dependent Inflammation in Cirrhotic Patients and Exacerbates Liver Injury in Mice - Amalia Tzoumpa, MS

0075 - Cancer-Induced Reprogramming of Macrophage Nucleotide Metabolism Dismantles Anti-Tumor Immunity - Shuang Liang, PhD

Risk Stratification of Donors and Candidates for Liver Transplantation

0192 - **Liver Transplantation for MetALD resembles ALD more than MASLD** - *Gene Y. Im, MD, FAASLD*

0129 - **The Liver Transplant Comorbidity Index (LTCl) : A Composite Index of Ambulatory Pre-LT Factors to Identify Patients at Increased Risk of Post-LT Mortality** - *Elizabeth Verna, MD, MS, FAASLD*

0105 - **Muscle mass, frailty and cardiopulmonary exercise testing: correlations and impact on liver transplant outcomes** - *Shivangi Gupta, MBBS*

0136 - **Coronary artery disease risk after liver transplantation is 2-fold higher than the general population: A nationwide Swedish cohort study of 2925 patients.** - *Christian Lewinter, MD, PhD*

0033 - **Abdominal Aortic Calcification – A Novel Cardiac Risk Prediction Tool in Liver Transplantation** - *Benjamin Cailles, MBBS (Hons)*

0180 - **The USC Psychosocial Checklist: A Tool to Remotely Screen Potential Liver Transplant (LT) Candidates with Alcohol-Associated Liver Disease (ALD) Prior to Hospital Transfer** - *Samantha Ramirez, DNP, FNP*

MASLD and MASH- New Therapies

0158 - **Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers** - *Mazen Nouredin, MD, MHSc*

0054 - **A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of Chiglitazar in NASH patients** - *Hong You, MD, PhD*

0166 - **GLP-1 Receptor Agonists have a potential to improve disease activity in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease** - *Andrea M. Tou, MD*

0170 - **AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study** - *Mary Rinella*

0037 - **PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY** - *Eric Lawitz*

0044 - Novel DGAT2 antisense inhibitor demonstrates significant histological benefit in biopsy-proven MASH patients with advanced liver fibrosis stage F3: Subset analysis of a 51-week multicenter randomized double-blind placebo-controlled phase 2 trial - Rohit Loomba, MD, MHSc, FAASLD

Advances in Pediatric Liver Disease: Basic and Translational

0058 - Plasma Multi-omics Indicate that Mitochondrial Stress and Altered Amino Acid Metabolism Contribute to Sarcopenia in Children with Genetic Cholestatic Liver Disease - Julia M. Boster, MD

0123 - Intrinsic NF- κ B activation controls cellular defects, viral susceptibility, and macrophage activation in biliary atresia cholangiocytes - Wenqi Li, MBBS

0215 - HUMAN DISEASE IS RECAPITULATED BY A NOVEL BILIARY ATRESIA THROUGH TARGETED ENDOTHELIAL DESTRUCTION SYSTEM - Kento Kurashima

0196 - Noninflammatory macrophages drive a fibrogenic gene program of periductal fibroblasts in pediatric primary sclerosing cholangitis. - Yunguan Wang, PhD

0036 - Circulating Activated Tissue Resident Memory CD8+ T cell Population is a Unique Feature of Pediatric Activated T-cell Acute Liver Failure and Hepatitis Associated Aplastic Anemia - Tamir Diamond, MD

0177 - Defining the liver immune microenvironment of Indeterminate Pediatric Acute Liver Failure with single-cell transcriptomics - Harry Sutton

11/17/2024

5:00 pm - 6:00 pm

The Role of Advanced Practice Providers in HCV and MASLD

0244 - RAPID START-UP OF A FIELD-BASED HEPATITIS C ELIMINATION PROGRAM ENABLED BY STATE FUNDED 340B INITIATIVE - Dylan Moore, BA/BS

0149 - Pharmacist-Driven Strategies Improve Hepatitis C CURES in a Variety of Practice Settings - Lindsey P. Sheehan, PharmD, MPA, MBA

0181 - Enhanced Patient Knowledge and Confidence in Managing Metabolic Dysfunction-Associated Steatotic Liver Disease Through Behavioral Resources and Intervention Through Digital Group Education (BRIDGE) - Lisa L. Catalli, MSN, NP-BC

11/17/2024
5:00 pm - 6:30 pm

Basic Mechanisms in the Pathogenesis and Prognosis of Alcohol-associated Liver Disease

0051 - **Pyruvate dehydrogenase kinase 4 Promotes Mitochondrial Dysfunction in Alcohol-Associated Liver Disease by Regulating ER-Mitochondria Interaction** - *THEMIS THOUDAM, PhD*

0080 - **Absence of intestinal Mucin-2 Promotes Goblet Cell-associated Antigen Passages Formation to Prevent Ethanol-induced Steatohepatitis in mice.** - *Maria Fernanda Raya Tonetti, PhD*

0156 - **The Lipidomic Profile discriminates between metabolic dysfunction-associated steatotic liver disease and combined metabolic dysfunction- and alcohol-related steatotic liver disease** - *Carolin Victoria Schneider, Prof., MD*

0145 - **Alpha diversity analysis of hepatic transcriptome reveals distinct signatures and predicts novel pathways in alcohol-related hepatitis** - *Sudrishti Chaudhary, PhD*

0038 - **Fecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis** - *Henriette Kreimeyer, MD*

0150 - **Role of FAF2, Fas associated factor family member 2, in the pathogenesis of alcohol-associated liver disease** - *Zhihong Yang, PhD*

MASLD and MASH- Diagnostic Criteria

0023 - **Prognostic value of the AASLD 2-step approach in the identification of advanced liver fibrosis in 16,603 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in the VCTE-Prognosis Study** - *Terry Cheuk-Fung Yip, PhD*

0049 - **VALIDATION OF THE MASEF SCORE FOR ITS DIAGNOSTIC ENRICHMENT UTILITY FOR AT-RISK MASH IN THE NIMBLE PROJECT** - *Gowthami Kanagalingam, MD*

0114 - **The proteome differentiates MetALD from MASLD and identifies patients at risk.** - *Niharika Jakhar, MS*

0106 - Type 2 diabetes and glycaemic control are associated with liver stiffness progression in people with MASLD: A Multicenter Prospective Study - *Daniel Q. Huang, MBBS, FRCP(UK), MMED, MCI*

0094 - Analysis of Non-Invasive Liver Biomarkers in a Phase II Trial of the Glucagon and GLP-1 Receptor Dual Agonist Survodutide in People with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis - *Mazen Nouredin, MD, MHSc*

0143 - The Steatosis-Associated Fibrosis Estimator (SAFE) Score Predicts Liver and Cardiovascular Outcomes: A UK Biobank Study - *W. Ray Kim, MD, FAASLD*

Genomics : A Path to Precision Medicine

0191 - LNP delivered Prime editors restore glycaemic control in humanized rodent models of Glycogen Storage Disease Type 1b (GSD1b) - *Vivian W. Choi, PhD*

0071 - Clinical and Genetic Characteristics of Patients with Histologic Steatosis Defined by Natural Language Processing in the MVP Liver Biopsy Cohort - *Samiran Mukherjee, MBBS*

0135 - Multimodal single-nuclei atlas of MASLD progression identifies a link to insulin resistance - *Laura Pikkupeura, PhD*

0160 - Validation of polygenic risk scores to predict MASLD Activity Score (MAS) and Advanced Fibrosis in a large cohort of patients with biopsy-proven MASLD - *Naga P. Chalasani*

0209 - Differential Impacts of GLP1R Gene Variants on Disease Risk and Treatment Efficacy in African Americans - *Eleonora Scorletti, MD, PhD*

Novel Interventions in the Diagnosis and Treatment of Liver Diseases

0121 - Outcomes of the Alcohol-Associated Hepatitis Bridge Clinic at a Safety-Net Hospital: A Prospective Pilot Study - *Divya Ayyala, MD*

0227 - Detection of Undiagnosed Liver Cirrhosis via Artificial Intelligence-enabled Electrocardiogram (DULCE): A Pragmatic, Cluster-Randomized Clinical Trial - *Douglas A. Simonetto, MD*

0040 - Applying the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Nomenclature with Natural Language Processing in a National Cohort - *Binu John, MD, MPH, FAASLD*

0067 - Improving Hepatitis B Screening Using EMR Hard-Stop in Resident Primary Care Clinic - *Beatriz Torre, MD*

0195 - Implementation of System-Wide HBsAg to HDV Ab Reflex Testing in a New York City Health System - *Anna Mageras, MPH*

0124 - A Health IT Intervention with Caregiver Engagement Significantly Reduces Avoidable Readmissions in A Multi-Center Randomized Clinical Trial of >450 participants: The HEROIC Trial - *Jawaid Shaw, MD*

11/18/2024

8:00 am - 9:30 am

Hepatotoxicity- New Insights Regarding Mechanisms and Prognostication

0092 - nR-value Greater Than Five Is Better Than Alkaline Phosphatase (AP) Less than Twice Normal Criterion for Identifying Hy's Law Cases in Clinical Trials - *Paul Hayashi, MD, MPH, FAASLD*

0101 - Hepatic Grp78/BiP Overexpression Protects Against Enhanced MASLD by Vinyl Chloride. - *Pooja R. Muddasani, BA/BS, MS*

0157 - Single-Cell Imaging Mass Cytometry Defines Immune Cell Composition and Spatial Interactions with Apoptotic Hepatocytes in Immune-mediated Liver Injury from Checkpoint Inhibitors (ILICI) and Autoimmune Hepatitis (AIH) - *Jacob M. Bogdanov, M.D.*

0093 - The Protective Role of Sulfiredoxin-1 (SRXN1) in Acetaminophen-Induced Liver Injury - *mengyun ke*

0079 - S-Adenosylmethionine Protects Against FOLFOX-Induced Liver Injury by Inhibiting Plasminogen Activator Inhibitor-1 in Mice - *Alexandra Gangi, MD*

0091 - Sankey Plots are Better than eDISH Based Plots for Initial DILI Assessment in Trials with Abnormal Baseline Liver Tests - *Jasmine Amirzadegan, PhD*

Hepatitis C- Epidemiology, Biomarkers, Fibrosis and HCC

0057 - Characteristics of persons treated for hepatitis C in the United States, 2014–2023 - *Eyasu H. Teshale, MD*

0154 - Chronic hepatic virus infection in mice leads to progressive fibrosis and HCC - *Mariana Nogueira Batista*

0128 - **A serum biomarker-based score to evaluate HCC risk in HCV-cured patients with cirrhosis** - *Hiroaki Kanzaki*

0085 - **Primary Graft Dysfunction and Major Adverse Cardiac Events after Hepatitis C Viremic Heart Transplantation to Aviremic Recipients** - *Ritika Mazumder, DO*

0063 - **Liver stiffness as a predictive factor for hepatocellular carcinoma development after sustained virologic response by direct-acting antivirals for chronic hepatitis C** - *Naoto Kawabe, MD, PhD*

0126 - **Same Day and Rapid Start HCV Management in La Bodega Clinic** - *Anthony Martinez, MD, FAASLD*

Biliary Physiology, Transport, Cholangiocyte Biology, Experimental Cholestasis

0116 - **Biliary senescence drives hepatocyte VCAM-1 expression and liver neutrophil infiltration** - *Marisa F. Ferreira, IMVM MScR AFHEA DipECVIM-CA MRCVS*

0018 - **Deletion of biliary atresia candidate gene *Pkd111* in isolated murine cholangiocytes cultures leads to enhanced basal and reactive pro-inflammatory gene expression** - *David Lee, MD*

0059 - **Heterozygous Knockout of Bile Salt Export Pump Induces Alterations in the Gut-Liver Axis Including Gut Microbiota in Mice Fed a High-fat Diet** - *Kazuya Okushin, MD, PhD*

0118 - **snRNAseq and GeoMx® spatial transcriptomics elucidate the cell-type-specific roles of lncRNA H19 in cholestatic liver injury** - *Grayson Way, M.S.*

0238 - **Notch signaling disruption and cellular crosstalk: dissecting the pathophysiology of bile duct paucity in Alagille syndrome using human liver organoids.** - *Massimiliano Paganelli, MD, PhD*

0245 - **The competing role of hepatic X-box binding protein 1 (Xbp1) in bile acid metabolism and bile-acid induced injury in murine chronic cholestasis** - *Alyssa Kriegermeier, MD*

Hepatitis B- Novel Therapeutic Targets and Preclinical Studies

0152 - **Tune-401 is a novel first-in-class epigenetic silencer developed for treatment of chronic Hepatitis B, with preclinical data showing strong, durable, and precise transcriptional repression of HBV DNA** - *Brian D. Cosgrove, PhD*

0107 - **Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model** - *Dai-tze Wu*

0183 - **A nucleosome switch primes Hepatitis B Virus infection** - *Robert Schwartz, MD, PhD, FAASLD*

0061 - **Dual-target (HBV and PD-L1 gene) siRNA achieved very high and rapid HBsAg clearance and antiviral activity in AAV-HBV mice** - *Zhiwei Yang, Ph.D.*

0082 - **The IFN-inducible MxB large GTPase attenuates HBV replication by activating the RIG-I innate immunity signaling pathway** - *Masazumi Onuki*

0155 - **Novel host factors in hepatitis B viral surface antigen production identified by genome-wide CRISPR-Cas9 knockout screen** - *Chloe Boehm*

MASLD Translational Targets

0142 - **Lipid induced Endothelial Intercellular Adhesion Molecule 1 (ICAM1) Promotes Liver Inflammation in Metabolic Dysfunction-Associated Steatohepatitis (MASH)** - *Qianqian Guo, MS*

0039 - **NADH-reductive stress links the antioxidant Cullin3-RING E3 ligase-NRF2 axis to regulation of hepatic steatosis and insulin sensitivity** - *Lijie Gu, PHD*

0115 - **Intrahepatic signaling by Netrin-1 exacerbates advanced fibrosis in nonalcoholic steatohepatitis** - *ya jie peng, MD*

0146 - **Role of OGT-TFF2 axis in intrahepatic crosstalk and MASH pathogenesis** - *Lei Zhang*

0193 - **Endogenous double-stranded RNA drives macrophage IRF3 activation promoting early metabolic dysfunction-associated steatohepatitis** - *Marcelle de Carvalho Ribeiro*

0078 - **The *PNPLA3* I148M variant initiates metabolic reprogramming in macrophages** - *Emmanuel D. Dixon, MSc*

From Bench to Bedside: State of the Art Diagnostics and Therapeutics in Genetic and Metabolic Liver Disease

0230 - **Liver-directed gene therapy normalizes toxic bile acid metabolite levels in the blood and brain of mice with cerebrotendinous xanthomatosis** - *Gloria Gonzalez-Aseguinolaza, PhD*

0081 - **ARBM-101 rescues fulminant Wilson Disease** - *Valentina Medici, MD, FAASLD*

0072 - **Convergent evolution of somatic escape variants in the liver in alpha-1 anti-trypsin deficiency.** - *Natalia Brzozowska, PhD*

0201 - **Advances in Prime Editing enable in vivo therapeutic correction of the *ATP7B* p.H1069Q and p.R778L mutations causing Wilson's disease** - *David P. Waterman, PhD*

0153 - **A first-in-class tool to predict future risk of portal hypertension, liver transplant and death in children with alpha-1-antitrypsin deficiency based on prospective data from the Childhood Liver Disease Research Network** - *Jeffrey Teckman, MD*

0016 - **The plasma proteomic profile of subjects with the *SERPINA1* Pi*ZZ genotype correlates with liver disease signatures: an analysis of population-level data from the UK Biobank Proteomics Project** - *Pavel Strnad*

11/18/2024

11:00 am - 12:30 pm

Human Cholestatic, PBC and other Biliary Disorders in Children and Adults

0043 - **One-year treatment with elafibranor in the phase III ELATIVE trial improves GLOBE and UK-PBC prognostic scores** - *Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD*

0219 - **The effect of obeticholic acid on inflammatory markers and fibrosis scores in POISE incomplete responders: a retrospective review of POISE, a phase 3 trial of obeticholic acid for the treatment of primary biliary cholangitis** - *David W. Victor, III, MD*

0186 - **Fibrate-Oca (FI-OCA) Study - a Global snapshot of PBC practice around the Globe** - *Vincenzo VR. Ronca, MD, MA*

0050 - **ASSERT-EXT: Final data from an open-label, phase 3 study of odevixibat in patients with Alagille syndrome** - *Nadia Ovchinsky*

0167 - **ATTENUATION, NEAR RESOLUTION, AND PREVENTION OF PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH SELADELPAR: A SECONDARY ANALYSIS OF PATTERNS OF PRURITUS CHANGE IN THE RESPONSE TRIAL** - *Andreas E. Kremer*

0164 - **EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL** - *Alejandra Villamil, MD*

Hepatitis B: Natural History and Biomarkers

0096 - **Performance of the CAGE-B and SAGE-B scores for prediction of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis** - *Lesley A. Patmore, MD*

0214 - **Alanine Aminotransferase Flares During Pregnancy or Postpartum Predict Increased HBeAg Seroclearance in Highly Viremic HBV-Infected Women** - *Wan-Hsin Wen, MD, PhD*

0090 - **Highly sensitive hepatitis B core-related antigen (HBcrAg) measurements can predict hepatocellular carcinoma (HCC) risk and hepatitis B surface antigen (HBsAg) loss in HBeAg-negative chronic hepatitis B patients** - *Tetsuya Hosaka, MD, FAASLD*

0189 - **Clinical outcomes of inactive hepatitis B surface antigen carriers with undetectable HBV DNA levels and low-level viremia** - *Yifan Pan*

0202 - **Impact of HBV Integration Events in HBV-Related Hepatocellular Carcinoma after Long-Term Antiviral Therapy on Clinical Indicators and Human Chromosomal Structure** - *Bobin Hu, MD*

0212 - **Expected eight-week versus twelve-week tenofovir alafenamide to prevent mother-to-child transmission of hepatitis B (TAF-HBV-MTCT): A multicenter, open-label, randomized controlled trial** - *Qing-Lei Zeng, M.D.*

Alcohol-associated Hepatitis: Updates in Diagnosis, Prognosis, and Therapy

0179 - Variable Treatment and Access to Liver Transplantation for Alcohol Associated Liver Disease: The California Liver Network - *Ashley Jowell, MD*

0163 - Artificial intelligence-derived granular histological markers of inflammation and fibrosis associate with progression in patients with alcohol-related steatohepatitis - *Chady Meroueh, M.D.*

0171 - AHEAD, A NOVEL VALIDATED MACHINE LEARNING MODEL FOR CLINICAL DIAGNOSIS OF ALCOHOL-ASSOCIATED HEPATITIS - *Ashwani K. Singal, MD, MS, FACG, FAASLD*

0206 - Alcohol-associated hepatitis remains a highly fatal condition: Results from a contemporary prospective multicenter cohort study from the United States - *Srinivasan Dasarathy, MD*

0236 - Use of pharmacological therapies for alcohol-associated hepatitis in Alberta: impact of shifting evidence and guideline-based recommendations - *Juan Abraldes, MD*

0198 - Effects of Timely Treatment on Outcomes of Lirsucosterol for Severe Alcohol-associated Hepatitis (AHFIRM Trial) - *Lance L. Stein, MD, FAASLD*

Portal Hypertension and Other Complications of Cirrhosis

0027 - The Portal Decompensation Score – A Validated Predictive Model of Portal Hypertension Related Liver Decompensation events in Cirrhosis - *Angus W. Jeffrey, MD*

0088 - Three-dimensional MR Elastography Predicts Clinically Significant Portal Hypertension in patients with cirrhosis: A Prospective Multicenter Study - *Xiaolong Qi, MD, MD*

0231 - Spleen stiffness is reliable in assessing hemodynamic response and prediction of rebleeding on beta-blocker therapy for secondary prophylaxis of variceal bleed-BETA-RESPONSE study. - *Akhil Deshmukh, MD DM*

0100 - The risk of portal vein thrombosis in patients with portal hypertension taking beta-blockers: A retrospective comparative study from a multi-institutional database. - *Hazem Abosheisha*

0068 - Carvedilol does not prevent decompensation in patients with compensated cirrhosis without high-risk varices with clinically significant portal hypertension defined by non-invasive tests: a randomised controlled trial - Syed Ahmed, MD

0032 - Carvedilol is Associated with Lower Mortality than Other Nonselective Beta Blockers in Patients with Cirrhosis - Michael Mullarkey, MD

Burdens to Bear: Trends in the Challenges and Costs of Liver Disease-Related Care

0199 - Opioid and Non-Opioid Analgesic Prescribing Among 398,080 Veterans with Cirrhosis: A Contemporary, Nationwide Analysis - Jessica B. Rubin, MD, MPH

0099 - The Impact of Weekend Admissions on Liver Transplant Outcomes in Acute Liver Failure in the United States - Melis G. Celdir, MD

0217 - Changes in hepatitis C virus infections after implementation of an expanded treatment program in New Mexico state prisons - Karla Thornton, MD

0020 - Characterization and Evolution of Caregiver Burden Before and After Recipient Liver Transplantation - Stacey Rolak, MD, MPH

0242 - TAP-LT: A Pilot Randomized Controlled Trial of a Transportation Assistance Program in Liver Transplant Candidates - Kali Zhou, MD, MAS

0228 - Value-based pricing of resmetirom for the treatment of metabolic dysfunction-associated steatotic liver disease: a cost-effectiveness analysis - Phuc Le, PhD, MPH

11/18/2024

2:00 pm - 3:30 pm

Translational Advances in Liver Fibrosis: From Hepatic Stellate Cells to Clinical Cell Therapy

0022 - CYP1B1⁺PRRX1⁺NR4A2⁺ hepatic stellate cells in alcohol-associated hepatitis - Hye Yeon Choi, Ph.D.

0065 - Hepatic stellate cells regulate liver size, zonation, metabolism, injury and regeneration via R-spondin 3 - Atsushi Sugimoto

0235 - With no lysine kinase 1 (WNK1)-mediated metabolism promotes hepatic stellate cell activation in a spatial manner during *in vivo* liver fibrosis. - *Alexander M. Washington, B.S.*

0035 - Wilms Tumor 1 and HIF-1 α induce hepatic stellate cell invasion that develops bridging fibrosis in chronic liver injury - *Michitaka Matsuda, MD, PhD*

0140 - Targeting the liver clock improves fibrosis by restoration of TGF- β signaling - *Emilie Crouchet*

0134 - Single Cell Fixed RNA Profiling reveals the interaction of macrophage and HSC via Semaphorin 4D-Plxnb2 to promote liver fibrosis - *Duc Pham, MD*

Therapeutic Approach to Alcohol Use Disorder (AUD) in Patients with Alcohol-Associated Liver Disease

0216 - Long-term Outcomes of Bariatric Surgery in Patients with Combined Metabolic Dysfunction and Increased Alcohol Consumption (MetALD) - *Seyedbabak Mirminachi, MD*

0210 - Therapeutic Efficacy of Varenicline Tartrate in Attenuating Alcohol Craving in Patients Suffering from Alcohol Use Disorder and Met-ALD. - *Vatsalya Vatsalya, MD PgD MSc MS FRSM*

0069 - Gastrointestinal and liver adverse effects of medical treatments of alcohol use disorder: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database - *Soo Young Hwang, MD, MPH*

0175 - Initiation of naltrexone is associated with lower rates of AKI, SBP, and mortality in patients with decompensated alcohol-associated cirrhosis and ascites - *Vinay Jahagirdar, MBBS*

0194 - Alcohol Behavior Change in Veterans with Unhealthy Alcohol Use: Assessing the Short Term Impact of Personalized Liver Biofeedback Using FibroScan with Brief Intervention - *Ponni V. Perumalswami, MD, FAASLD*

0148 - Video-Based Multi-Center Collaboration with County Public Health Department to Enhance Delivery of Alcohol-Associated Liver Disease Care by Community Providers - *Brian P. Lee, MD*

Hepatobiliary Neoplasia- Risk, Therapy and Prognosis

0182 - **R0N0 resection for perihilar cholangiocarcinoma offers survival similar to transplantation: A multicentre pan-European study** - *Raj Prasad, MS, MCh, FRCS*

0200 - **Neoadjuvant Therapy Prior to Orthotopic Liver Transplantation (OLT) for Hepatocellular Carcinoma (HCC): Ablation and Radiation associated with a higher complete tumor necrosis rate than Chemoembolization** - *Maarouf A. Hoteit, MD*

0052 - **Camrelizumab combined with Lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: a prospective, single-arm trial (Cal Era study)** - *Mengya Zang*

0087 - **Predicting Survival Among Patients with Early- to Intermediate-Stage HCC: Miami Liver cancer Estimator of Survival (MILES) Score** - *David S. Goldberg, MD, MSCE*

0034 - **Machine learning radiomics based on CT to predict response to lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma** - *Gang Chen*

0120 - **Outcomes of Child-Pugh B patients treated with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for unresectable hepatocellular carcinoma (uHCC) in a Real-World Cohort** - *Shalini K. Bansal, BA/BS*

Diagnostic, Therapeutic and Prognostic Challenges in Autoimmune Liver Diseases

0185 - **TNFalpha as a key inflammatory mediator in Autoimmune Hepatitis (AIH): molecular basis and successful proof-of-concept phase IIA clinical trial of infliximab induction therapy** - *Jan Philipp Weltzsch, MD*

0240 - **Predicting outcomes in autoimmune hepatitis pregnancy** - *Yooyun Chung, MBBS*

0042 - **Fecal cytolyisin is associated with a poorer outcome in patients with primary sclerosing cholangitis** - *Burcin Özdirik, MD*

0109 - **Alkaline phosphatase and fibrosis markers are prognostic for outcome in recurrent primary sclerosing cholangitis after liver transplantation** - *Lise Katrine Engesæter, MD*

0133 - **Quantitative MRCP metrics have utility in assessing changes in biliary tree health in PSC patients: a ten-year evaluation** - *Kartik Jhaveri, MD*

0151 - Associations Between Biomarkers and Magnetic Resonance Imaging-Derived ANALI Score in Patients with Primary Sclerosing Cholangitis: Analysis from the Phase 3 PRIMIS Study - Michael Trauner, MD

Portal Hypertension and Other Complications of Cirrhosis- Treatments

0144 - Efficacy of Carvedilol + Ivabradine vs Carvedilol alone for left ventricular diastolic dysfunction in cirrhosis and impact on decompensation, cardiac function and survival; an open label randomized controlled trial - Madhumita Premkumar, MBBS, MD, DM

0218 - Conjugated, Sulfated, and Amphipathic Bile Acids are Associated with Acute Kidney Injury Recovery in Patients with Decompensated Cirrhosis: An Untargeted Metabolomics Study - Giuseppe Cullaro, MD

0055 - Major Variations in 90-day Mortality post-hospital Discharge among Inpatients with Cirrhosis: A Prospective Cohort Study for the CLEARED Consortium - Ramazan Idilman, MD, FAASLD

0187 - Natural history and predictors of outcomes in patients with liver cirrhosis after index variceal hemorrhage from fundal varices - Sagnik Biswas, DM

0190 - Targeting lower serum albumin with long term albumin administration improves outcomes of recurrent ascites in patients with decompensated cirrhosis- Final results of the randomised controlled trial - Rakhi Maiwall, MD, DM

0048 - Measurement of effective albumin concentration significantly improved prediction of one year mortality in patients with acutely decompensated cirrhosis without acute-on-chronic liver failure - Chenxi Zhang

Interplay of the Gut-Liver Axis Across the Spectrum of Liver Disease

0159 - Ultradeep sequencing of the Gut Microbiome shows Progressive Weaponization of Enterobacteriaceae with Cirrhosis progression through Mobile Genetic Elements which may not recover after FMT - Jasmohan Bajaj, MD, FAASLD

0113 - Diminished Enteric High-Density Lipoprotein 3 and Low LPS and Spingosine-1-Phosphate Binding in Portal Blood Associated with High Mortality in Alcoholic Cirrhosis - Sukriti Baweja, PhD

0122 - Pasteurized Akkermansia muciniphila Suppresses Hepatocellular

Carcinoma Growth by Regulating the CD8 Memory Response and Treg Cells Through Modulation of STING Expression - *Chun-Ying Wu, MD, PhD, MPH, LL.M*

0111 - Metabonomics and metagenomics for diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease - *Zhou Tiantian*

0086 - The Role of Regulating Gut Tryptophan Metabolism on Anti-Tumor Immunity in Liver Cancer and its Mechanism - *Liang Wen, Dr., MD*

0102 - Gut microbiome pattern impacts treatment response in primary biliary cholangitis - *Liu Qiaoyan*

11/18/2024

5:00 pm - 6:30 pm

Updates in Acute on Chronic Liver Failure

0117 - Phenotypes, natural course, and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF): Results from the ICA-Global AKI Study - *Elsa Solà, MD PhD*

0127 - Serum albumin-binding capacity correlates with serum albumin structural alterations and clinical outcomes in patients with acutely decompensated cirrhosis and acute-on-chronic liver failure - *Chenxi Zhang*

0073 - Initiation of renal replacement therapy in critically ill patients with cirrhosis/chronic liver disease: a secondary analysis of STARRT-AKI trial - *Constantine J. Karvellas, MD, SM, FRCPC, FCCM*

0029 - Inhibition of necroptosis reduces inflammation, neutrophil activation, liver fibrosis and improves multiorgan damage (kidney function and neuroinflammation) in a murine model of alcohol-induced ACLF - *Marti Ortega-Ribera, PhD*

0095 - Autologous macrophage therapy decreases major clinical outcomes in patients with compensated cirrhosis: extended data from a randomized controlled Phase 2 trial - *Stuart J. Forbes, MB CHB, FRCP(Ed), PhD*

0243 - Individual nutrition support in patients with HBV-ACLF at nutrition risk: preliminary results of a randomized controlled clinical trial - *Liang Peng*

Exploring Disparities and Determinants in Liver Disease and Care

0119 - **Equitable and Inclusive Policies Towards Sexual and Gender Minoritized Patients at Liver Transplant Centers** - *Alan Hutchison, MD, PhD*

0066 - **Jail Length of Stay Does Not Account for Gender Differences in Hepatitis C Treatment Initiation in the New York City Jail System, 2019–2023** - *Chibuzo U. Enemchukwu, MD, MS*

0162 - **People of African/African American ancestry harbor fewer liver disease-related risk alleles than European (White) ancestry** - *Ning Ma, PhD*

0097 - **Representation of Gender, Racial, and Ethnic Minorities In Hepatology Clinical Trials** - *Kin Li, DO*

0026 - **Racial/Ethnic and Sex Differences in Major Adverse Cardiovascular Events and Major Adverse Liver Outcomes Among Steatotic Liver Disease Subtypes: A National Cohort Study** - *Pedro Ochoa-Allemant, MD*

0178 - **Acceptability of and Experience with Health Related Social Needs Screening Among Patients with Chronic Liver Disease: A Qualitative Study** - *Rebecca G. Kim, MD, MAS*

Hepatitis D: Natural History and Treatment

0104 - **A Prospective / Retrospective Provincial and National Laboratory Serosurvey of HDV Antibody Prevalence in Referred and Non-Referred Samples in Canada.** - *Emma R. Lee, PhD*

0021 - **Association of Hepatitis Delta Virus Infection and Hepatocellular Carcinoma, Hepatic Decompensation, All-cause and Liver-Related Death in a U.S National Cohort** - *Binu John, MD, MPH, FAASLD*

0213 - **HBs isoforms as innovative biomarkers in predicting virological response to bulevirtide monotherapy in patients with chronic hepatitis delta** - *Stefano D'Anna, PhD*

0139 - **Long-term Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (SAVE-D)** - *Elisabetta Degasperi*

0239 - **BJT-778, anti-HBsAg monoclonal antibody, achieved 100% virologic response in subjects with chronic hepatitis D (CHD): phase 2 study results** - *Kosh Agarwal*

0074 - Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 24 primary endpoint analysis from the Phase 2 SOLSTICE trial - *Tarik Asselah*

Cell-Based Approaches to Understanding and Treating Liver Disease

0233 - Decoding and Targeting Hepatocyte Senescence in MASLD: From Identification to Treatment - *Kuo Du, PhD*

0237 - In vivo screening for targets to block immune escape in hepatocellular carcinoma - *Chunmiao Cai, PhD*

0220 - Hepatic lymphangiogenesis regulates biliary cell proliferation during liver regeneration after partial hepatectomy - *Savneet kaur*

0234 - The role of Sirt2 and downstream signaling in hepatocellular carcinoma progression - *Claudia Rose Keating*

0077 - Autophagy impairment leads to multiple forms of cell death in the liver - *X Charlie Dong, PhD*

0205 - X-box binding protein 1 (XBP1) transcriptionally regulates small heterodimer partner (SHP) expression in the liver. - *Xiaoying Liu, PhD*

Hepatobiliary Neoplasia- Tumor Microenvironment and Carcinogenesis

0173 - Multiplexed single-cell analysis reveals distinct tumor-immune microenvironment linked to premetastatic niche formation in steatotic liver - *Jieun Kim*

0138 - Liver cancer chemoprevention by targeting the histamine receptor 2 and using PLSec as a biomarker - *Emilie Crouchet*

0084 - Contribution of myeloid cell-derived HMGB1 to the development of hepatocellular carcinoma - *Sai Santosh Babu Komakula, M.Pharm., Ph.D.*

0169 - Regnase-1 down-regulation contributes to myeloid cell intermediated ICC development - *Yu Sato*

0098 - Lysosomal autophagy-based degradation of hepatocellular carcinoma PD-L1 modulates tumor macrophage polarization to activate anti-tumor immunity - *Xu Gao, MD*

0041 - Enhancing Cytotoxic CD8+ T Cell Response for Liver Cancer Treatment using polyIC-Containing Ionizable Lipid Nanoparticles via activating Hepatocellular Type I IFN pathway - *Yingluo Liu, PhD*

Advances in Treatment of Hepatitis C

0030 - Evaluating the safety and efficacy of SOF/VEL treatment and prophylactic use of TAF in patients with chronic HBV/HCV coinfection: A multicenter study - *Ning Lin*

0222 - Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study - *Catherine A. Chappell*

0053 - Factors associated with long-term risk of liver-related and non-liver-related death after sustained virologic response in patients with hepatitis C virus treated with direct-acting antiviral - *Yuki Tahata*

0130 - Effectiveness of Glecaprevir/Pibrentasvir for 8 Weeks in People Taking Antipsychotics, Buprenorphine/Naloxone, or Illicit Drugs - *Marc D. Rizzo, PharmD*

0070 - Predictors of Treatment Failure and Resistance Associated Substitutions in Patients with Chronic Hepatitis C Infections - HCV Elimination Experience from the Punjab Model in India - *Radha K. Dhiman, MD, DM, FACG, FRCP, FAASLD*

0168 - Rapid Hepatitis C Test and Treat with Peer Support at Opioid Treatment Programs (RAPID HCV): A multicenter randomized control trial. - *Oluwaseun Falade-Nwulia, MBBS, MPH*